Fever Patterns, Cytokine Profiles, and Outcomes in COVID-19

Abstract Background Prolonged fever is associated with adverse outcomes in dengue viral infection. Similar fever patterns are observed in COVID-19 with unclear significance. Methods We conducted a hospital-based case–control study of patients admitted for COVID-19 with prolonged fever (fever >7 days) and saddleback fever (recurrence of fever, lasting <24 hours, after defervescence beyond day 7 of illness). Fever was defined as a temperature of ≥38.0°C. Cytokines were determined with multiplex microbead-based immunoassay for a subgroup of patients. Adverse outcomes were hypoxia, intensive care unit (ICU) admission, mechanical ventilation, and mortality. Results A total of 142 patients were included in the study; 12.7% (18/142) of cases had prolonged fever, and 9.9% (14/142) had saddleback fever. Those with prolonged fever had a median duration of fever (interquartile range [IQR]) of 10 (9–11) days for prolonged fever cases, while fever recurred at a median (IQR) of 10 (8–12) days for those with saddleback fever. Both prolonged (27.8% vs 0.9%; P < .01) and saddleback fever (14.3% vs 0.9%; P = .03) were associated with hypoxia compared with controls. Cases with prolonged fever were also more likely to require ICU admission compared with controls (11.1% vs 0.9%; P = .05). Patients with prolonged fever had higher induced protein–10 and lower interleukin-1α levels compared with those with saddleback fever at the early acute phase of disease. Conclusions Prolonged fever beyond 7 days from onset of illness can identify patients who may be at risk of adverse outcomes from COVID-19. Patients with saddleback fever appeared to have good outcomes regardless of the fever.

[1]  E. Romano Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19. , 2021, Arquivos brasileiros de cardiologia.

[2]  A. Zangrillo,et al.  Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study , 2020, The Lancet Rheumatology.

[3]  G. Gao,et al.  Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19 , 2020, Journal of Allergy and Clinical Immunology.

[4]  Antonio Bertoletti,et al.  A Dynamic Immune Response Shapes COVID-19 Progression , 2020, Cell Host & Microbe.

[5]  Q. Ye,et al.  The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 , 2020, Journal of Infection.

[6]  Q. Ye,et al.  The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 , 2020, Journal of Infection.

[7]  W. Gong,et al.  Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. , 2020, JAMA cardiology.

[8]  Haiyan Qiu,et al.  Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study , 2020, Lancet. Infectious Diseases (Print).

[9]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[10]  H. Dai,et al.  Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19 , 2020, International Journal of Infectious Diseases.

[11]  Lei Liu,et al.  Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome , 2020, medRxiv.

[12]  J. Low,et al.  Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. , 2020, JAMA.

[13]  Qiurong Ruan,et al.  Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.

[14]  Zheng Zhao,et al.  Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response measures , 2020, The Lancet.

[15]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[16]  Y. Leo,et al.  De-isolating Coronavirus Disease 2019 Suspected Cases: A Continuing Challenge , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[18]  L. Chen,et al.  [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]. , 2020, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

[19]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[20]  Cindy Leung,et al.  Association of a Workplace Sales Ban on Sugar-Sweetened Beverages With Employee Consumption of Sugar-Sweetened Beverages and Health. , 2020, JAMA internal medicine.

[21]  Y. Ye,et al.  The Regulation of Seventeen Inflammatory Mediators are Associated with Patient Outcomes in Severe Fever with Thrombocytopenia Syndrome , 2018, Scientific Reports.

[22]  C. Dinarello Overview of the IL‐1 family in innate inflammation and acquired immunity , 2018, Immunological reviews.

[23]  P. Fallahi,et al.  Interferon-γ-induced protein 10 in Dengue Virus infection. , 2016, Clinica Terapeutica.

[24]  Sheena McCormack,et al.  Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial , 2016, The Lancet.

[25]  Yanli Wang,et al.  Cytokine and Chemokine Levels in Patients with Severe Fever with Thrombocytopenia Syndrome Virus , 2012, PloS one.

[26]  Y. Carmi,et al.  IL-1α and IL-1β Recruit Different Myeloid Cells and Promote Different Stages of Sterile Inflammation , 2011, The Journal of Immunology.

[27]  R. Flavell,et al.  Recent advances in IL-22 biology. , 2011, International immunology.

[28]  K. Sauer,et al.  IL-21 Is Required to Control Chronic Viral Infection , 2009, Science.

[29]  L. Rosenwasser,et al.  Biologic activities of IL-1 and its role in human disease. , 1998, The Journal of allergy and clinical immunology.

[30]  R. Weinstein,et al.  Magnitude and prevention of nosocomial infections in the intensive care unit. , 1997, Infectious disease clinics of North America.

[31]  M. Reale,et al.  Blocking the interleukin-1 receptor inhibits leukotriene B4 and prostaglandin E2 generation in human monocyte cultures. , 1992, Cellular immunology.

[32]  Melbourne Victoria,et al.  A Ministry of Health , 1917, Nature.

[33]  Ong Ye,et al.  THE STRAITS TIMES , 2017 .

[34]  C. Gabay,et al.  Interleukin-1 receptor antagonist: role in biology. , 1998, Annual review of immunology.